
Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1117 | 1117 | 1045 | 1283 | 2037 | 1702 |
Fund Return | 11.73% | 11.73% | 4.49% | 8.65% | 15.3% | 5.46% |
Place in category | 100 | 100 | 320 | 136 | 77 | 78 |
% in Category | 19 | 19 | 90 | 34 | 22 | 34 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
JHancock Disciplined Value Mid Cap | 12.43B | -1.67 | 5.71 | 8.61 | ||
JHancock Disciplined Value I | 7.3B | 0.00 | 7.68 | 9.08 | ||
John Hancock Variable Insurance Tri | 6.68B | -4.36 | 8.71 | 12.16 | ||
JHVIT Strategic Equity Allocation T | 6.4B | -0.96 | 7.06 | 9.17 | ||
JHancock Disciplined Value Mid Cap6 | 5.56B | -1.67 | 5.82 | 8.72 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Dodge & Cox International Stock | 40.34B | 9.68 | 7.60 | 4.90 | ||
Fidelity Series International VVV | 15.42B | 14.01 | 11.24 | 6.62 | ||
Causeway International Value Instl | 11.86B | 10.13 | 12.73 | 6.11 | ||
Vanguard International Value Inv | 12.28B | 4.58 | 4.54 | 4.65 | ||
DFA International Value I | 9.2B | 11.20 | 9.82 | 6.30 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Novartis | CH0012005267 | 3.61 | 89.38 | +0.72% | |
Sandoz | CH1243598427 | 2.81 | 33.07 | +1.04% | |
BAE Systems | GB0002634946 | 2.76 | 1,744.50 | +3.04% | |
Alibaba | KYG017191142 | 2.74 | 109.90 | +1.57% | |
Sony | JP3435000009 | 2.70 | 3,366.0 | +2.19% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Sell | Strong Sell | Sell |
Technical Indicators | Neutral | BUY | Strong Sell |
Summary | Neutral | Neutral | Strong Sell |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review